Short report:: High efficacy of two artemisinin-based combinations (artesunate plus amodiaquine and artemether plus lumefantrine) in Caala, Central Angola
Short report:: High efficacy of two artemisinin-based combinations (artesunate plus amodiaquine and artemether plus lumefantrine) in Caala, Central Angola
复制标题
DOI：
10.4269/ajtmh.2006.75.143
复制
发表时间：
2006-07-01
影响因子：
3.3
通讯作者：
Balkan, Suna
中科院分区：
文献类型：
--
作者：
Guthmann, Jean-Paul;Cohuet, Sandra;Balkan, Suna
2004年4月，137名6-59个月的无并发症恶性疟原虫（Pf）疟疾儿童（卡阿拉，安哥拉中部）被随机分配接受蒿甲醚-本芴醇（Coartem）或青蒿琥酯+阿莫地喹（ASAQ）治疗。随访28天后，Coartem组有2/61例（3.2%）复发性寄生虫血症，ASAQ组有4/64例（6.2%）复发性寄生虫血症（P = 0.72），均归类为PCR基因分型后的再次感染（两组的治愈率均为100% [95%CI：94-100]）。仅1例患者（ASAQ组）在第28天有配子母细胞，而基线时为5例（Coartem）和3例（ASAQ）。与基线相比，两组在随访28天后贫血均显著改善（Coartem：从54.1%降至13.4%; ASAQ：从53.1%降至15.9%）。我们的研究结果是在卡阿拉的两个组合的高效率的青睐。既然复方蒿甲醚已被选为新的一线抗疟疾药物，挑战是确保这种药物的可用性和充分使用。
In April 2004, 137 children 6-59 months of age with uncomplicated Plasmodium falciparum (Pf) malaria (Caala, Central Angola) were randomized to receive either artemether-lumefantrine (Coartem) or artesunate + amodiaquine (ASAQ). After 28 days of follow-up, there were 2/61 (3.2%) recurrent parasitemias in the Coartem group and 4/64 (6.2%) in the ASAQ group (P = 0.72), all classified as re-infections after PCR genotyping (cure rate = 100% [95%CI: 94-100] in both groups). Only one patient (ASAQ group) had gametocytes on day 28 versus five (Coartem) and three (ASAQ) at baseline. Compared with baseline, anemia was significantly improved after 28 days of follow-up in both groups (Coartem: from 54.1% to 13.4%; ASAQ: from 53.1% to 15.9%). Our findings are in favor of a high efficacy of both combinations in Caala. Now that Coartem has been chosen as the new first-line anti-malarial, the challenge is to insure that this drug is available and adequately used.